Featured Press Releases

LEQEMBI® (lecanemab), a treatment for Alzheimer

LEQEMBI® (lecanemab), a treatment for Alzheimer's disease, is now available in South Korea, expanding access to innovative care

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

  • 22 Jul 2024

The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor...

Sensitech acquires Berlinger & Co. to expand life sciences cold chain solutions

Sensitech acquires Berlinger & Co. to expand life sciences cold chain solutions

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

  • 3T Biosciences
  • 03 Mar 2026
Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

  • Matricelf Ltd.
  • 27 Feb 2026
ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

  • ARUP Laboratories
  • 26 Feb 2026
Neurizon Begins Dosing of NUZ-001 in HEALEY ALS Platform Trial

Neurizon Begins Dosing of NUZ-001 in HEALEY ALS Platform Trial

  • Neurizon Therapeutics Limited
  • 27 Feb 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.